Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06439966
Status:
AVAILABLE
Last Update Posted:
2024-06-03
First Post:
2024-05-28
Brief Title:
Expanded Access to ABBV-787
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
Expanded Access to ABBV-787
Status:
AVAILABLE
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an expanded access program EAP for eligible participants This program is designed to provide access to ABBV-787 prior to approval by the local regulatory agency Availability will depend on territory eligibility A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patients medical history and program eligibility criteria
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None